Adaptive Biotechnologies Corporation (ADPT)
Nasdaq: ADPT · Biological Products, (No Diagnostic Substances) · Seattle, WA · filing with the SEC since 2009
Who owns Adaptive Biotechnologies Corporation
As filed with the SECHolders of 5% or more
2
Viking Global Investors LP holds 18.8% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
11
report now, of 29 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Viking Global Investors LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 6.7% in Apr 17, 2025
Nikko Asset Management Americas, Inc.
SCHEDULE 13G/A · filed Feb 13, 2025 · Common stock, par value $0.0001 per share · reported falling below 5%
Sumitomo Mitsui Trust Group, Inc.
SCHEDULE 13G/A · filed Feb 4, 2025 · Common stock, par value $0.0001 per share · reported falling below 5%
Millennium Management LLC
SCHEDULE 13G/A · filed Jan 27, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Rubric Capital Management LP
SCHEDULE 13G/A · filed Jul 9, 2025 · Common stock, par value $0.0001 per share · reported falling below 5%
ARK Investment Management LLC
SCHEDULE 13G/A · filed Jun 6, 2025 · Common Stock · reported falling below 5%, from 5.2% in May 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ADPT reports owning in othersstakes of 5% or more, and other ties
Adaptive Biotechnologies Corporation reports no stake in another company in the record.
Insider tradesForm 4
181sales
0purchases
159sales on a scheduled plan
11people selling
$131Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 43 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Robins Chad M | CEO and Chairman | 17 | $38.5M | 11 | 0 | $0 |
| Robins Harlan S | Chief Scientific Officer | 16 | $29.5M | 14 | 0 | $0 |
| Rubinstein Julie | President and COO | 100 | $22.5M | 100 | 0 | $0 |
| Benzeno Sharon | Chief Commercial Ofc Imm Med | 6 | $14.7M | 5 | 0 | $0 |
| Lo Francis | Chief People Officer | 17 | $14.0M | 16 | 0 | $0 |
| Piskel Kyle | Chief Financial Officer | 6 | $3.6M | 3 | 0 | $0 |
| Neupert Peter M | director | 3 | $3.1M | 0 | 0 | $0 |
| Griffin Michelle Renee | director | 3 | $2.0M | 2 | 0 | $0 |
| Bobulsky Susan | Chief Commercial Officer, MRD | 10 | $1.4M | 9 | 0 | $0 |
| Hershberg Robert | director | 3 | $1.1M | 0 | 0 | $0 |
| Owen Katey Einterz | director | 1 | $200,000 | 0 | 0 | $0 |